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Abstract
We investigated the faecal carriage prevalence of extended-spectrum β-lactamase production in Escherichia coli (EP-
EC) and/or Klebsiella pneumoniae (EP-KP) and risk factors associated with carriage among adult study subjects in
Finland, Germany, Latvia, Poland, Russia and Sweden (partner countries). The aim was to get indicative data on the
prevalence of ESBL-carriage in specific populations in the region. Faecal samples were collected from four study
populations and screened on ChromID-ESBL and ChromID-OXA-48 plates. Positive isolates were further
characterised phenotypically. Our results show a large variation in carrier prevalence ranging from 1.6% in Latvia
to 23.2% in Russia for EP-EC. For the other partner countries, the prevalence of EP-EC were in increasing numbers,
2.3% for Germany, 4.7% for Finland, 6.6% for Sweden, 8.0% for Poland and 8.1% for all partner countries in total.
Carriers of EP-KP were identified only in Finland, Russia and Sweden, and the prevalence was < 2% in each of
these countries. No carriers of carbapenemase-producing isolates were identified. This is the first study reporting
prevalence of carriers (excluding traveller studies) for Finland, Latvia, Poland and Russia. It contributes with
important information regarding the prevalence of EP-EC and EP-KP carriage in regions where studies on carriers
are limited.
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Introduction
Asymptomatic faecal carriage of extended-spectrum β-
lactamase-producing bacteria like Escherichia coli (EP-EC)
or Klebsiella pneumoniae (EP-KP) contributes to dissemina-
tion of antibiotic resistance in the community which could
ultimately lead to increased resistance prevalence in
community-acquired infections. One important risk factor
for acquiring a bloodstream infection (BSI) with ESBL-
producing Enterobacteriaceae is a previous ESBL-positive
culture (carriage or infection) [1–3]. The number of people
at risk for ESBL-BSI could therefore increase if community
carriage of EP-EC and EP-KP increases. Potential roles of
carriers in the epidemiology of EP-EC and EP-KP are how-
ever not clear. Carriers in the community could serve as a link
between resistance in animals and environment and clinical
infections in humans [4–7]. However, the role of carriers has
not been addressed in large surveillance initiatives. Extensive
knowledge of the antibiotic resistance epidemiology is impor-
tant for rational and effective antibiotic use for both hospital
and community-acquired infections [8].
Most studies of ESBL-carriers have addressed the risk of
becoming a carrier when travelling to high prevalence coun-
tries, a risk that has been established in several studies [9–12].
However, the prevalence and risk factors associated with car-
riage in different populations in the community is not well
studied.
Recruiting healthy study subjects is challenging since
they in general are hard to reach and their participation
is either relying on their will to do good for public
health without personal gain or monetary compensation.
Populations like university students, army recruits and
primary care visitors are often recruited to be investigat-
ed for carrier prevalence [13]. Germany and Sweden
have performed separate large studies on carriers, with
study subjects representing a cross section of the popu-
lation, where the carrier prevalence of EP-EC reported
were at 6.3% and 4.7%, respectively [14, 15].
We designed a cross-sectional study on the preva-
lence of intestinal EP-EC and EP-KP carriers in study
populations in Finland, Germany, Latvia, Poland, Russia
and Sweden (referred to as partner countries) simulta-
neously in 2015–2017. The aim was to investigate the
prevalence in countries where carriage of EP-EC and
EP-KP had never been studied and to follow up on
the development in countries that had previous studies
on carriage. Moreover, we wanted to build capacity in
the respective countries to perform studies on asymp-
tomatic carriage. Information on possible risk factors
for EP-EC and EP-KP carriage were collected by a
questionnaire directed to all study subjects.
Materials and methods
Common study protocols for collection of faecal samples and
questionnaires were developed and approved by all partners.
Written informed consent was obtained from all study subjects
included in the study. Ethical permission was gained by each
partner country individually.
Each country sampled from the following regions: Turku
and Helsinki region (Finland), Riga region (Latvia), Leipzig
region (Germany), Silesian voivodeship (Poland), Smolensk
region (Russia), Stockholm region (Sweden). Samples were
collected between October 2015 and January 2017 with the
aim to collect 250 samples per country. Faecal samples were
collected by 1 ml Eswab (Copan Diagnostics Inc., Mantua,
Italy) from populations defined beforehand by partners.
Defined sample populations were individuals visiting differ-
ent types of primary care centres (defined as non-inpatient
care), elective day surgery patients, university students and
advertising on internet-based sites for recruiting study sub-
jects. Women and men between 18 and 65 years that had
resided in the country for at least 1 year, not taken antibiotics
during the last 3 months and that did not have current diar-
rhoea at the time of sampling were included in the study. In
Germany, only the age criteria was enforced and not the other
exclusion criteria.
Faecal samples were cultured by plating 100 μl of liquid
from the Eswab Collection Kit medium on each of the com-
mercially available plates, ChromeID ESBL and ChromeID
OXA-48 (bioMérieux, Marcy-l’Étoile, France) and incubated
for 18–24 h in 35–37 °C. After the incubation, colonies were
isolated and species identification determined by MALDI-
TOF (Biotyper, Bruker Corporation, the Netherlands).
Antibiotic susceptibility tests were performed on E. coli and
K. pneumoniae isolates with disc diffusion and gradient tests
according to EUCAST methodology and breakpoints (http://
www.eucast.org/clinical_breakpoints/ accessed on 2018-07-
06). Resistance rates were defined as the percentage of non-
susceptible (R + I) isolates to the antibiotic in question. For
Germany, equivalentmethods for selection of resistant isolates
with CHROMagar™ ESBL and CHROMagar™ KPC plates
were used and the methods were previously published [11].
Phenotypic β-lactamase identification was performed with
combination disc testing with clavulanic acid in combination
with cefotaxime or ceftazidime for ESBL-production (Becton
Dickinson, Cockeysville, MD, USA) and cloxacillin in com-
bination with cefotaxime or ceftazidime for AmpC-
production (Rosco Diagnostica A/S, Taastrup, Denmark).
For carbapenemase-production, the following neosensitab
combinations were used: meropenemwith phenylboronic acid
for detecting KPC, meropenem with dipicolinic acid for de-
tecting MBL and temocillin for detecting OXA-48 (KPC,
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MBL and OXA-48 Confirmation Kit, RoscoDiagnostica A/S,
Taastrup, Denmark). Multi-drug resistance (MDR) was de-
fined according to Magiorakos et al. 2012 as resistance to
three or more classes of antibiotics tested [16].
All study subjects received the same questionnaire (trans-
lated to respective native language) in all partner countries
(Online resource 1).
All data from partner countries were reported, summarised
and analysed using the same methods and performed at the
Public Health Agency of Sweden. Univariate risk analysis
was performed only for non-carriers and EP-EC-carriers that
had both contributed with a sample and a questionnaire.
Carriers and non-carriers were also compared between coun-
tries within different subpopulations (between-country analy-
ses). Firth’s logistic regression model was used to calculate
odds ratios and confidence intervals for the risk analyses. All
statistical analysis was performed in R statistical software
(version 3.2.5).
Results
In total, 99 EP-EC and 8 EP-KP were isolated from 1211
faecal samples collected from study populations in Finland,
Germany, Latvia, Poland, Russia and Sweden (Tables 1 and
2). Samples were collected from primary care 44.3%, adverts
22.6%, university students 19.5% and elective day surgery
13.5% and the study populations varied between partner coun-
tries (Table 1).
The prevalence of EP-EC carriers varied from 1.6% in
Latvia to 23.2% in Russia with a total prevalence of 8.1%
for all partner countries (Table 1). Prevalence of EP-EC in
other partner countries were in increasing numbers, 2.3% for
Germany, 4.7% for Finland, 6.6% for Sweden and 8.0% for
Poland (Fig. 1). For EP-KP, no carriers were identified in
Germany, Latvia and Poland, while Finland, Russia and
Sweden identified 2 (1.1%), 5 (2.0%) and 1 (0.3%) carriers,
respectively, (Fig. 1). No carriers of carbapenemase-producing
isolates including OXA-48-like producers were identified. In
Russia, two carriers were identified that were positive for both
EP-EC and EP-KP. Neither of these study subjects had been
hospitalised during the last 6 months but one had taken anti-
biotics the last 12 months and worked within the health care
sector.
Susceptibility testing (Table 2) of EP-EC showed over 35%
resistance to trimethoprim, trimethoprim-sulfamethoxazole
and ciprofloxacin. Moreover, 87% of EP-EC were MDR in
total for all partner countries (Table 2). Low overall resistance
rates (less than 11%) were recorded for nitrofurantoin,
mecillinam, meropenem and fosfomycin. For the 8 EP-KP
isolates, the antibiotic resistance profiles resembled those of
EP-EC (Table 2).
A risk analysis for each partner country was performed to
investigate potential risk factors within each country
(Online resource 2). Risk factors were only identified for
Russian study subjects, the age groups 31–50 and 51–65 years
were at higher risk for being carriers compared to study sub-
jects that were 18–30 years (OR 2.3 for both ages
Online resource 2). Also Russian study subjects that had been
hospitalised during the last 6 months were at higher risk for
being carriers compared to no hospitalisation in Russia (OR
5.2) Online resource 2.
Low number of carriers, who travelled to different destina-
tions, did not allow for a valid risk analysis. No risk analysis
was performed for EP-KP carriers due to too few positive
study subjects. Pooling of EP-EC and EP-KP isolates in the
risk analysis was not considered due to general differences in
epidemiology of the species [17].
Discussion
In this multi-country study, we investigated the carrier point
prevalence of EP-EC and EP-KP and showed large differ-
ences between the study populations in Finland, Germany,
Latvia, Poland, Russia and Sweden where Russia had consid-
erably higher numbers of EP-EC carriers compared to the
other partner countries (Table 1, Fig. 1). This is the first carrier
prevalence study (excluding traveller studies) ever reported
for Finland, Latvia, Poland and Russia. The geographical set-
ting, including countries from Northern and Eastern Europe
and Russia, is also unique since comparisons between these
countries are lacking. No carriers of carbapenemase-
producing E. coli and K. pneumoniae (including OXA-48-
like producers) were identified, which indicate that the preva-
lence of these is likely to be low. Carriers of EP-KP were
identified in half of the partner countries but the prevalence
was not exceeding 2%, which suggests a low overall preva-
lence in the community.
Although parameters such as antibiotic treatment (18–
39%), hospitalisation (2–8%) and age (median 28–43 years)
differed between countries (Table 1), none of these factors
alone explains the higher prevalence seen for Russia since
other countries had study populations that were older
(Poland), had higher antibiotic treatment (Latvia) or
hospitalisation history (Poland).
The large difference in the prevalence of carriers seen be-
tween the neighbouring countries Latvia and Russia (1.6 vs
23.2%) could be due to variation in study population charac-
teristics. However, age, sex, antibiotic treatment and
hospitalisation history were similar in Russia and Latvia
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(Table 1) indicating that our results reflect an actual difference
in carriage rate between these countries in the studied
populations.
The high prevalence reported for Russian carriers was not
unexpected since widespread dissemination of ESBL-
producers in Russian hospitals has started earlier than in many
















Trimethoprim 38 (9–76) 75 (19–99) 75 (19–99) 57 (18–90) 54 (41–68) 63 (38–84) 57 (46–67)
Mecillinam 0 (0–37) 0 (0–60) 0 (0–60) 0 (0–41) 4 (0–12) 11 (1–33) 4 (1–10)
Nitrofurantoin 0 (0–37) 0 (0–60) 0 (0–60) 0 (0–41) 0 (0–6) 5 (0–26) 1 (0–6)
Trimethoprim-sulfamethoxazole 38 (9–76) 75 (19–99) 75 (19–99) 57 (18–90) 54 (41–68) 44 (22–69) 53 (43–63)
Amoxicillin-clavulanic acid 0 (0–37) 50 (7–93) 0 (0–60) 0 (0–41) 14 (6–26) 44 (22–69) 18 (11–28)
Ciprofloxacin 63 (25–92) 50 (7–93) 50 (7–93) 57 (18–90) 65 (51–77) 53 (29–76) 61 (50–70)
Meropenem 0 (0–37) 0 (0–60) 0 (0–60) 0 (0–41) 0 (0–6) 0 (0–18) 0 (0–4)
Cefoxitin 0 (0–37) 25 (1–81) 0 (0–60) 0 (0–41) 5 (1–15) 11 (1–33) 6 (2–13)
Cefotaxime 100 (63–100) 100 (40–100) 100 (40–100) 100 (59–100) 90 (79–96) 100 (82–100) 94 (87–98)
Ceftazidime 100 (63–100) 100 (40–100) 75 (19–99) 100 (59–100) 70 (57–82) 100 (82–100) 82 (73–89)
Gentamicin 25 (3–65) 25 (1–81) 25 (1–81) 43 (10–82) 21 (11–34) 11 (1–33) 21 (14–31)
Fosfomycin 0 (0–37) 0 (0–60) 0 (0–60) 0 (0–41) 4 (0–12) 5 (1–26) 3 (1–9)
MDR 88 (47–100) 100 (40–100) 75 (19–99) 100 (59–100) 84 (72–93) 90 (67–99) 87 (79–93)
MDR multi drug resistance
Fig. 1 Prevalence of carriers of EP-EC (ESBL producing E. coli) and EP-KP (ESBL producing K. pneumoniae) in partner countries (map
generated with EMMa (ECDC Map Maker) tool)
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European countries and has been reported exceeding 60% in
recent studies [18–20]. Regarding the risk analysis, Russia
was the only country where risk factors could be identified
(higher age than 30 and previous hospitalisation,
Online resources 2) but further studies are needed to establish
if these are valid risk factors.
Sweden and Finland showed a similar prevalence, which is
also supported by results from other surveillance initiatives
[17, 21, 22]. This is likely due to similarities in healthcare
structure, antibiotic stewardship and travel patterns in the gen-
eral population. A Finnish travellers study conducted between
2009 and 2010 showed a prevalence of 1.2% pre-travel, which
was lower than what we found in this study. However, a dif-
ferent study population and an earlier study date could explain
the higher prevalence seen in our study [10]. In Sweden, a
previous study identified a 4.7% national carrier prevalence
[15]. The 6.6% identified in this study could be an increase
over time but it is hard to draw any conclusion since the
method for recruitment of study subjects was different.
The prevalence for German study subjects (2.3%) was low-
er than expected since previous studies in a similar setting
have shown prevalence numbers of 6.3–6.8% [11, 14].
The only previous data on carriage in Poland was from a
study on 20 healthy children in 2002 where one was positive
for ESBL-producing E. coli. The study population is too dif-
ferent and too small to compare the data to our results [23].
This study has limitations when it comes to study popula-
tion, representativeness and comparability. The varying size of
the study populations rendered large confidence intervals in
some study populations (Table 1). Difference in culture and
healthcare structure made it difficult to perform a study with a
random sample from the population. Moreover response rate
data was not available for analysis because the collection of
this data either failed or was not possible due to the sampling
method. Sampling was only done at a regional level and not
validated for being representative for the entire country.
Therefore the external validity of our results is unknown
which makes it hard to estimate how well our findings reflect
the general carriage in the community in partner countries.
With that said, the majority of studies done on carriers to
estimate community prevalence were done on similar study
populations [13, 24].
Future studies of the molecular epidemiology of the iso-
lates in the EP-EC population will bring more information on
relatedness between the isolates in the studied countries.
Regarding the screening plates used, ChromeID-ESBL and
ChromeID-OXA-48, isolates that were resistant to only
carbapenemases (non-OXA-48) with no ESBL co-resistance
could have been negative in the screen. For Germany, isolates
that were non-ESBL OXA-48 producers could possibly have
been missed due to the use of different plates. However, the
current epidemiology of carbapenemase-producing E. coli is
mainly driven by plasmids which harbours co-resistance to
several antibiotics, including cephalosporins, and would be-
cause of this grow on the ChromeID-ESBL plates. Therefore,
we estimate that no, or very few, carbapenemase-producing
isolates were missed because of the screening strategy.
Only the age exclusion criteria were enforced in Germany,
which was a bias compared to other countries study popula-
tions. However, this did not contribute to an increased preva-
lence in Germany (2.3%) and neither did the higher travel
frequency (due to that a vaccination clinic was used for the
recruitment).
To conclude, our results should be regarded as a first
insight into the prevalence of ESBL-carriers in this re-
gion, but more studies are needed to get a comprehen-
sive understanding of the situation in partner countries.
Surveillance of resistance in carriers is an important
complement to the surveillance of clinical isolates since
it measures the penetration of antibiotic resistance in
society. It helps us to elucidate potential dissemination
routes and what sectors that contribute to the increasing
resistance seen for clinical isolates.
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